Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci181893 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Soumya Poddar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Kite, a Gilead Company, Santa Monica, California, USA. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Lymphoma, Follicular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kite, a Gilead Company.
Abstract (Originalsprache)
BACKGROUND Axicabtagene ciloleucel (axi-cel), anti-CD19 chimeric antigen receptor (CAR) T cell therapy, demonstrated remarkable efficacy with manageable toxicity in relapsed/refractory indolent B cell lymphomas in the ZUMA-5 trial. METHODS Here, we report associations of product attributes, serum biomarkers, clinical features, and tumor characteristics with outcome in 124 patients with follicular lymphoma (FL). RESULTS In univariate and multivariate analyses, pretreatment inflammatory markers, including TNF-α and IL-12p40, as well as total metabolic tumor volume (TMTV), associated with disease progression. Conversely, T-naive–like product phenotype associated with improved outcome, particularly in patients with high TMTV. These covariates improved risk stratification when combined with the FL International Prognostic Index. Postinfusion, CAR T cell expansion associated with improved outcome, while serum inflammatory and immunomodulatory markers, including TNF-α, associated with disease progression and occurrence of high-grade cytokine release syndrome or neurologic events, presenting targets to improve the therapeutic index of axi-cel in FL. Tumor gene expression profiling revealed that both type I and II IFN signaling associated with disease progression and higher expression of T cell exhaustion markers, including TIM3 and LAG3. Pre- or posttreatment CD19 expression on tumor was not associated with outcome. CONCLUSION These findings offer insights into mechanisms of resistance and toxicity, risk stratification, and strategies for development of next generation CAR-T approaches. TRIAL REGISTRATION ClinicalTrials.gov NCT03105336. FUNDING Kite, a Gilead Company.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kite, a Gilead Company, Santa Monica, California, USA.
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Förderung
- Kite, a Gilead Company
Zitieren
APA
Poddar, S., Yan, J., Tiwari, G., Rinchai, D., Budka, J., Zhang, W., Peng, W., Salunkhe, S., Davis, M., Song, Q., Beygi, S., Miao, H., Mattie, M., Shen, R. S., Jacobson, C. A., Bedognetti, D., Filosto, S., & Neelapu, S. S. (2025). Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci181893
Vancouver
Poddar S, Yan J, Tiwari G, Rinchai D, Budka J, Zhang W, et al. Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma. Journal of Clinical Investigation. 2025. doi:10.1172/jci181893
BibTeX
@article{Poddar2025,
author = {Poddar, Soumya and Yan, Jiali and Tiwari, Gayatri and Rinchai, Darawan and Budka, Justin and Zhang, Wangshu and Peng, Weixin and Salunkhe, Shruti and Davis, Madison and Song, Qinghua and Beygi, Sara and Miao, Harry and Mattie, Mike and Shen, Rhine S and Jacobson, Caron A and Bedognetti, Davide and Filosto, Simone and Neelapu, Sattva S},
title = {Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci181893}
}
EUVIMED